Clinical Trial

Pembrolizumab and Radiotherapy in Liver Cancer

Study Description

Study of Pembrolizumab and Radiotherapy in Liver Cancer

This is a phase 2 study whose purpose is to assess the efficacy of the combination of pembrolizumab and stereotactic body radiotherapy (SBRT) in patients with advanced hepatocellular carcinoma (HCC) who have experienced disease progression after treatment with sorafenib.


Locations Selected Location


Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Pembrolizumab

Pembrolizumab is a humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.

Radiation - Stereotactic Body Radiotherapy (SBRT)

SBRT involves delivery of high doses of radiation therapy in smaller fractions

Additional Information

Official Study Title

Pembrolizumab and Stereotactic Radiotherapy Combined in Subjects With Advanced Hepatocellular Carcinoma - A Phase II Study

Clinical Trial ID


ParticipAid ID